Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

“At a median follow-up of 10 months, we had not reached the median duration of response yet, and 76.2% of the patients at 6 months had ongoing responses. This is an exciting signal of activity. Notably, we’ve seen responses both from patients who have previously gotten enfortumab vedotin-efjv and those who have not, so this is quite an active agent.”

Funda Meric-Bernstam, MD, chair, the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director, the Institute for Personalized Cancer Therapy (IPCT), the Nellie B. Connally Chair in Breast Cancer, the University of Texas MD Anderson Cancer Center, discusses updated efficacy and safety data from the ongoing phase 1 TROPION-PanTumor01 study (NCT03401385) evaluating datopotamab deruxtecan (Dato-DXd; Datroway) in locally advanced or metastatic urothelial cancer.